Up to $350 million over 5 years targeting antimicrobial resistance. What’s not to like?
Some antibiotics researchers are questioning how the funding is being directed from CARB-X, a public–private partnership announced yesterday. Backed by the US government (if Congress approves the funds), the Wellcome Trust and others, CARB-X seeks to speed antibiotics development by improving on promising molecules.
Kim Lewis, an antibiotics researcher at Northeastern University, says more basic science is what’s really needed—like developing compounds that can puncture the outer membranes of super microbes.